- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FCS Expanding Employment, Educational Opportunities For Underserved Students
Florida Cancer Specialists & Research Institute (FCS) announced a partnership with Strayer University’s Grads to Work program that will help prepare a diverse population of students for job opportunities and support them while they continue their education.
Fort Myers, Florida — Florida Cancer Specialists & Research Institute (FCS) announced a partnership with Strayer University’s Grads to Work program that will tap individuals interested in long-term employment in the health care sector who may not otherwise have means to support their education and provide them with a pathway to a nonclinical associate degree as they pursue their career goals.
After successfully completing a 5-week workforce readiness course, candidates will initially be eligible to interview for open positions at Florida Gulf Coast locations. Additional positions will become available throughout the practice’s nearly 100 locations as the program develops.
“Our statewide practice is at the forefront of cancer care and clinical research. We believe that combining employment and educational opportunities will create enormous opportunity and positive change in communities across Florida,” said Nathan H. Walcker, MBA, chief executive officer, FCS.
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
